Safety and tolerability of the glutamate antagonist cgs 19755 (selfotel) in patients with acute ischemic stroke: Results of a phase iia randomized trial

James Grotta; Wayne Clark; Bruce Coull; L. Creed Pettigrew; Bruce Mackay; Larry B. Goldstein; Irene Meissner; Deborah Murphy; Linda Larue

doi:10.1161/01.STR.26.4.602

Safety and tolerability of the glutamate antagonist cgs 19755 (selfotel) in patients with acute ischemic stroke: Results of a phase iia randomized trial

James Grotta, Wayne Clark, Bruce Coull, L. Creed Pettigrew, Bruce Mackay, Larry B. Goldstein, Irene Meissner, Deborah Murphy, Linda Larue

Neurology

Research output: Contribution to journal › Article › peer-review

173 Scopus citations

Abstract

Background and Purpose CGS 19755 is a competitive N-methyl-D-aspartate (NMDA) receptor antagonist that limits neuronal damage in animal stroke models. The objectives of this multicenter (7 centers), randomized, double-blind, placebo-controlled, ascending-dose phase IIa study were to evaluate the safety and tolerability of CGS 19755 and obtain pharmacokinetic and preliminary data on its efficacious dose range in patients treated within 12 hours of hemispheric ischemic stroke.

Original language	English (US)
Pages (from-to)	602-605
Number of pages	4
Journal	Stroke
Volume	26
Issue number	4
DOIs	https://doi.org/10.1161/01.STR.26.4.602
State	Published - Apr 1995

ASJC Scopus subject areas

Clinical Neurology
Cardiology and Cardiovascular Medicine
Advanced and Specialized Nursing

Access to Document

10.1161/01.STR.26.4.602

Cite this

@article{a7bc9a70a7be40288a4d9c1de0113d3d,

title = "Safety and tolerability of the glutamate antagonist cgs 19755 (selfotel) in patients with acute ischemic stroke: Results of a phase iia randomized trial",

abstract = "Background and Purpose CGS 19755 is a competitive N-methyl-D-aspartate (NMDA) receptor antagonist that limits neuronal damage in animal stroke models. The objectives of this multicenter (7 centers), randomized, double-blind, placebo-controlled, ascending-dose phase IIa study were to evaluate the safety and tolerability of CGS 19755 and obtain pharmacokinetic and preliminary data on its efficacious dose range in patients treated within 12 hours of hemispheric ischemic stroke.",

author = "James Grotta and Wayne Clark and Bruce Coull and Pettigrew, {L. Creed} and Bruce Mackay and Goldstein, {Larry B.} and Irene Meissner and Deborah Murphy and Linda Larue",

year = "1995",

month = apr,

doi = "10.1161/01.STR.26.4.602",

language = "English (US)",

volume = "26",

pages = "602--605",

journal = "Stroke",

issn = "0039-2499",

publisher = "Lippincott Williams and Wilkins",

number = "4",

}

TY - JOUR

T1 - Safety and tolerability of the glutamate antagonist cgs 19755 (selfotel) in patients with acute ischemic stroke

T2 - Results of a phase iia randomized trial

AU - Grotta, James

AU - Clark, Wayne

AU - Coull, Bruce

AU - Pettigrew, L. Creed

AU - Mackay, Bruce

AU - Goldstein, Larry B.

AU - Meissner, Irene

AU - Murphy, Deborah

AU - Larue, Linda

PY - 1995/4

Y1 - 1995/4

N2 - Background and Purpose CGS 19755 is a competitive N-methyl-D-aspartate (NMDA) receptor antagonist that limits neuronal damage in animal stroke models. The objectives of this multicenter (7 centers), randomized, double-blind, placebo-controlled, ascending-dose phase IIa study were to evaluate the safety and tolerability of CGS 19755 and obtain pharmacokinetic and preliminary data on its efficacious dose range in patients treated within 12 hours of hemispheric ischemic stroke.

AB - Background and Purpose CGS 19755 is a competitive N-methyl-D-aspartate (NMDA) receptor antagonist that limits neuronal damage in animal stroke models. The objectives of this multicenter (7 centers), randomized, double-blind, placebo-controlled, ascending-dose phase IIa study were to evaluate the safety and tolerability of CGS 19755 and obtain pharmacokinetic and preliminary data on its efficacious dose range in patients treated within 12 hours of hemispheric ischemic stroke.

UR - http://www.scopus.com/inward/record.url?scp=0028921447&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028921447&partnerID=8YFLogxK

U2 - 10.1161/01.STR.26.4.602

DO - 10.1161/01.STR.26.4.602

M3 - Article

C2 - 7709405

AN - SCOPUS:0028921447

SN - 0039-2499

VL - 26

SP - 602

EP - 605

JO - Stroke

JF - Stroke

IS - 4

ER -

Safety and tolerability of the glutamate antagonist cgs 19755 (selfotel) in patients with acute ischemic stroke: Results of a phase iia randomized trial

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this